Involvement of serotonergic system in the effect of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test

Journal of Pharmacological Sciences

Volumn 127, Issue 1, 2015, Pages 57-61

  Fukumoto, Kenichi ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Depression; Ketamine; Metabotropic glutamate 5 receptor antagonist; Novelty suppressed feeding test; Serotonin

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; METABOTROPIC GLUTAMATE 5 RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; FENCLONINE; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; RITANSERIN; SEROTONIN; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; LATENT PERIOD; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN FUNCTION; SEROTONINERGIC SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEEDING BEHAVIOR; PHYSIOLOGY;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; FEEDING BEHAVIOR; FENCLONINE; MALE; MICE; PIPERAZINES; PYRIDINES; QUINOXALINES; RECEPTOR, METABOTROPIC GLUTAMATE 5; RITANSERIN; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 84924084873     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2014.09.003     Document Type: Article

References (36)

1. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, and D.S. Charney Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
2. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
3. S.J. Mathew, J.W. Murrough, M. aan het Rot, K.A. Collins, D.L. Reich, and D.S. Charney Riluzole for relapse prevention following intravenous ketamine in treatment resistant depression: a pilot randomized, placebocontrolled continuation trial Int J Neuropsychopharmacol 13 2010 71 82
4. L. Ibrahim, N. Diazgranados, D.A. Luckenbaugh, R. Machado-Vieira, J. Baumann, and A.G. Mallinger Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression Prog Neuropsychopharmacol Biol Psychiatry 35 2011 1155 1159
5. M. aan het Rot, K.A. Collins, J.W. Murrough, A.M. Perez, D.L. Reich, and D.S. Charney Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol Psychiatry 67 2010 139 145
6. J.H. Krystal, G. Sanacora, and R.S. Duman Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond Biol Psychiatry 73 2013 1133 1141
7. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, and M. Iwata mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
8. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, and P.F. Cheng NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
9. H. Yamanaka, C. Yokoyama, H. Mizuma, S. Kurai, S.J. Finnema, and C. Halldin A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques Transl Psychiatry 4 2014 e342
10. N. Nishitani, K. Nagayasu, N. Asaoka, M. Yamashiro, H. Shirakawa, and T. Nakagawa Raphe AMPA receptors and nicotinic acetylcholine receptors mediate ketamine-induced serotonin release in the rat prefrontal cortex Int J Neuropsychopharmacol 17 2014 1321 1326
11. K. Fukumoto, M. Iijima, and S. Chaki Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test Psychopharmacology (Berl) 231 2014 2291 2298
12. A. Deschwanden, B. Karolewicz, A.M. Feyissa, V. Treyer, S.M. Ametamey, and A. Johayem Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study Am J Psychiatry 168 2011 727 734
13. S. Morley-Fletcher, J. Mairesse, A. Soumier, M. Banasr, F. Fagioli, and C. Gabriel Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats Psychopharmacology (Berl) 217 2011 301 313
14. A.H. Iyo, A.M. Feyissa, A. Chandran, M.C. Austin, S. Regunathan, and B. Karolewicz Chronic corticosterone administration down-regulates metabotropic glutamate receptor 5 protein expression in the rat hippocampus Neuroscience 169 2010 1567 1574
15. I.V. Belozertseva, T. Kos, P. Popik, W. Danysz, and A.Y. Bespalov Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests Eur Neuropsychopharmacol 17 2007 172 179
16. A. Pilc, A. Kłodzińska, P. Brański, G. Nowak, A. Pałucha, and B. Szewczyk Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats Neuropharmacology 43 2002 181 187
17. A. Pałucha, P. Brański, B. Szewczyk, J.M. Wierońska, K. Kłak, and A. Pilc Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist Pharmacol Biochem Behav 81 2005 901 906
18. Z.A. Hughes, S.J. Neal, D.L. Smith, S.J. Sukoff Rizzo, C.M. Pulicicchio, and S. Lotarski Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression Neuropharmacology 66 2013 202 214
19. S. Chaki, Y. Ago, A. Palucha-Paniewiera, F. Matrisciano, and A. Pilc mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants Neuropharmacology 66 2013 40 52
20. A. Pałucha-Poniewiera, P. Brański, J.M. Wierońska, K. Stachowicz, A. Sławińska, and A. Pilc The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent Psychopharmacology (Berl) 231 2014 97 107
21. K. Stachowicz, K. Gołembiowska, M. Sowa, G. Nowak, E. Chojnacka-Wójcik, and A. Pilc Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent Neuropharmacology 53 2007 741 748
22. M. Iijima, K. Fukumoto, and S. Chaki Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test Behav Brain Res 235 2012 287 292
23. H. Koike, K. Fukumoto, M. Iijima, and S. Chaki Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression Behav Brain Res 238 2013 48 52
24. K.A. Holick, D.C. Lee, R. Hen, and S.C. Dulawa Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor Neuropsychopharmacology 33 2008 406 417
25. G. Quesseveur, H.T. Nguyen, A.M. Gardier, and B.P. Guiard 5-HT2 ligands in the treatment of anxiety and depression Expert Opin Investig Drugs 21 2012 1701 1725
26. C.A. Heidbreder, M. Bianchi, L.P. Lacroix, S. Faedo, E. Perdona, and R. Remelli Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo Synapse 50 2003 269 276
27. I. Smolders, R. Clinckers, A. Meurs, D. De Bundel, J. Portelli, and G. Ebinger Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action Neuropharmacology 54 2008 1017 1028
28. S.R. Bodnoff, B. Suranyi-Cadotte, D.H. Aitken, R. Quirion, and M.J. Meaney The effects of chronic antidepressant treatment in an animal model of anxiety Psychopharmacology (Berl) 95 1988 298 302
29. A.L. Halberstadt, V.D. Lehmann-Masten, M.A. Geyer, and S.B. Powell Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice Psychopharmacology (Berl) 215 2011 81 92
30. J.L. Griffiths, and T.A. Lovick Co-localization of 5-HT 2A -receptor- and GABA-immunoreactivity in neurones in the periaqueductal grey matter of the rat Neurosci Lett 326 2002 151 154
31. W.M. Abi-Saab, M. Bubser, R.H. Roth, and A.Y. Deutch 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex Neuropsychopharmacology 20 1999 92 96
32. G. Sanacora, G.F. Mason, and J.H. Krystal Impairment of GABAergic transmission in depression: new insights from neuroimaging studies Crit Rev Neurobiol 14 2000 23 45
33. D.M. O'Leary, V. Movsesyan, S. Vicini, and A.I. Faden Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism Br J Pharmacol 131 2000 1429 1437
34. J.M. Mathiesen, N. Svendsen, H. Bräuner-Osborne, C. Thomsen, and M.T. Ramirez Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP Br J Pharmacol 138 2003 1026 1030
35. F. Gasparini, K. Lingenhöhl, N. Stoehr, P.J. Flor, M. Heinrich, and I. Vranesic 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacology 38 1999 1493 1503
36. X. Li, A.B. Need, M. Baez, and J.M. Witkin Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice J Pharmacol Exp Ther 319 2006 254 259